Cytotoxicity testing is a critical step in the preclinical evaluation of biomaterials and medical devices, with extracellular matrix (ECM)‐based biomaterials constituting a significant category. The current ISO 10993‐5:2009 standard, Biological Evaluation of Medical Devices‐Part 5: Tests for In Vitro Cytotoxicity, delineates four metabolic assays that primarily rely on colorimetric methods and colony formation. However, relying solely on colorimetric assays or colony formation fails to provide precise insights into cell function/activity and may yield false‐positive results, contributing to interlaboratory discrepancies. This study systematically evaluated ISO 10993‐5‐recommended assays for ECM‐based commercial products, specifically assessing the impact of key assay variables including cell types, contact mode (test extracts versus test material itself), and media components (with or without serum) on biological outcomes. These evaluations support the development of more accurate and robust test methods. While all four assays indicated the noncytotoxic nature of the test samples, metabolic activity readings varied substantially depending on the serum presence, cell types, and assay method employed. To address these limitations and achieve more precise insights into cellular activity, cell membrane integrity (live/dead staining), cell‐ECM attachment (actin cytoskeleton), proliferation (Ki67), and apoptosis (annexin V) were analyzed. Notably, despite observing increased metabolic activity (100%–150%) under serum‐free conditions measured using MTT and XTT assays, live/dead and actin staining showed no corresponding changes in cell viability or attachment, and Ki67 indicated only ∼15% proliferation. Annexin V staining was detected only in human primary dermal fibroblasts, highlighting their greater reliability over L929 cells for detecting apoptosis. These findings provide a valuable reference for researchers, regulatory bodies, and industry stakeholders in refining cytotoxicity testing protocols and guiding future ISO 10993‐5 revisions for more reliable assessment of biomaterials and medical devices.
17 June 2019 in International Journal of Polymeric Materials and Polymeric Biomaterials
Human amniotic membrane (AM) is reported to possess remarkable therapeutic potential for wound healing due to its inherent bioactive and biocompatible properties. However, poor handling characteristics have limited its clinical use on wounds to a great extent. Reinforcement of AM with a biodegradable polymer is therefore expected to provide adequate mechanical and handling nature. Poly-[Lactide-co-Glycolide-co-Caprolactone] terpolymer incorporated with silver nanoparticles and coated with fibrin is used in this study to reinforce the membrane which delivers bioactive molecules to the wound site without wound contraction. This combination scaffold exhibited desirable properties with excellent biocompatibility for potential use in wound healing applications.
Human skin architecture comprises several interpenetrating macromolecules seen as organized extracellular matrix (ECM). For regeneration of critical-size acute and chronic wounds, substituting the damaged tissue with artificially assembled biomolecules offer an interactive milieu . This study reports development and preclinical evaluation of a biodegradable and immuno-compatible scaffold for regeneration of critical-size (4 × 4 cm 2 ) full-thickness rabbit burn wounds. The designed wound care product comprises synthetic terpolymer poly(L-Lactide-co-Glycolide-co-Caprolactone) (PLGC), human clinical-grade fibrin (FIB), and hyaluronic acid (HA), termed as PLGCFIBHA. Here, clotting of fibrinogen concentrate (FC) with excess thrombin in the scaffold create an interpenetrating FIB network harnessed with adhesive molecules like fibronectin and laminin present in FC with exogenous HA to produce ECM-like milieu on porous PLGC. Penetrating into porous PLGCFIBHA, long term study showed a regulated fibroblast growth resulting in non-fibrotic dermal-like tissue in vitro . The freeze-dried PLGCFIBHA with residual thrombin facilitated suture-less, hemostatic matrix adhesion to the wound bed in vivo . By 28 d, mature and scar-less epidermis-dermis formation with skin appendages was evident in the PLGCFIBHA-treated wound area. Both negative (untreated/sham) and positive (commercial matrix-treated) control wounds showed incomplete regeneration. The PLGCFIBHA-treated wounds were comparable to native skin by 56 d. These regenerative outcomes upon single application of PLGCFIBHA confirms its potential translational value for wound care.
13 November 2021 in Journal of Biomedical Materials Research Part B: Applied Biomaterials